News | January 21, 2014

ASA releases recommendations for pain medicine, imaging


January 21, 2014 — As part of ABIM Foundation’s Choosing Wisely campaign, the American Society of Anesthesiologists  (ASA) released its second list of five targeted, evidence-based recommendations to support conversations between patients and physician anesthesiologists about what care is really necessary.
 
  1. Avoid imaging studies for acute low-back pain without specific indications.
    Unnecessary imaging in the first six weeks after pain begins may reveal incidental findings that divert attention and increase risk of unhelpful surgery. Clinical indications include history of cancer with potential metastases, known aortic aneurysm and progressive neurologic deficit.
  2. Don’t prescribe opioid analgesics as first-line therapy to treat chronic non-cancer pain.
    Physicians should first consider multimodal therapy, including non-drug treatments such as behavioral and physical therapies. Medication such as NSAIDs and anticonvulsants should be trialed prior to commencing opioids.
  3. Don’t prescribe opioid analgesics as long-term therapy to treat chronic non-cancer pain until risks are considered and discussed with the patient.
    Physicians should inform patients of risks including addiction, and physicians and patients should sign written agreements identifying each party’s responsibilities and consequences of non-compliance. Physicians should be cautious in co-prescribing opioids and benzodiazepines, and should proactively evaluate side effects such as constipation and low testosterone or estrogen.
  4. Don’t use intravenous sedation for diagnostic and therapeutic nerve blocks, or joint injections as a default practice.
    When possible, diagnostic procedures, therapeutic nerve blocks and joint injections should be performed with local anesthetic alone rather than with propofol, midazolam or ultrashort-acting opioid infusions. Intravenous sedation can be used after evaluation and discussion of risks, including interference in assessing acute pain-relieving effects of the procedure and potential for false positive responses. ASA Standards for Basic Anesthetic Monitoring should be followed in cases where moderate or deep sedation is provided or anticipated.
  5. Avoid irreversible interventions for non-cancer pain that carry significant costs and/or risks.
    Irreversible interventions such as peripheral chemical neurolytic blocks or peripheral radiofrequency ablation may carry significant long-term risks of weakness, numbness or increased pain.
Members of the ASA Committee on Pain Medicine submitted recommendations for this list, which were then voted on and researched to provide supporting evidence. 
 
For more information: www.asahq.org, www.choosingwisely.org

Related Content

News | Endoscopes

Oct. 22, 2025 — Fujifilm Healthcare Americas Corp. has launched its advanced endoscopy platform, the ELUXEO 8000 ...

Time October 23, 2025
arrow
News | X-Ray

Oct. 22, 2025 — Imaging technology company Adaptix has begun live imaging trials as part of a research program at the ...

Time October 22, 2025
arrow
News | Contrast Media

Oct. 21, 2025 — Subtle Medical, Inc., a provider of AI-powered medical imaging solutions, has announced positive ...

Time October 21, 2025
arrow
News | Radiology Imaging | UC San Diego Health

Oct. 16, 2025 — A strategic collaboration between UC San Diego Health and GE HealthCare will focus on bringing advanced ...

Time October 20, 2025
arrow
News | Artificial Intelligence

Oct. 20, 2025 — Viz.ai has launched of Viz Assist, a suite of autonomous AI agents that significantly enhance how care ...

Time October 20, 2025
arrow
News | Point-of-Care Ultrasound (POCUS)

Oct. 15, 2025 — GE HealthCare has announced the latest advancement in its Venue family of point-of-care ultrasound ...

Time October 16, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

September 24, 2025—According to the American Journal of Roentgenology (AJR), MRI can reliably identify lateral meniscal ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Oct. 01, 2025 – Nuclidium AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time October 02, 2025
arrow
News | Radiology Business | Harvey L. Neiman Health Policy Institute

Sept. 30, 2025 — A new study from the Harvey L. Neiman Health Policy Institute found that attrition (i.e., exit) from ...

Time October 02, 2025
arrow
News | Computed Tomography (CT)

Sept. 26, 2025 — At the American Society for Radiation Oncology (ASTRO) 2025 annual meeting in San Francisco, Calif ...

Time September 29, 2025
arrow
Subscribe Now